Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNK-007 Post-ASCT in Multiple Myeloma
NCT02955550Phase 1Completed
- Sponsor
- Celularity Inc.
- Start
- Jan 2017
- Primary completion
- Jul 2018
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of taniraleucel in multiple myeloma (MM), sponsored by Celularity Inc. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 2 more. Started Jan 2017; status: completed.
02
Drugs
taniraleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02955550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955550.